Enzyme Replacement Therapy Market Forecast to 2027 - Covid-19 Impact and Global Analysis - ByEnzyme Type (Pegademase, Velaglucerase Alfa, Agalsidase Beta, Imiglucerase, Taliglucerase, Laronidase, Alglucosidase Alfa, Galsulfase, Idursulfase, Pancreatic Enzymes, Other Enzymes); Therapeutic Conditions (Gaucher's Disease, Fabry's Disease, Pompe's Disease, SCID, MPS, Others) and Geography
Report Code: TIPRE00008474 No. of Pages: 150 Category: Biotechnology Status: Upcoming
MARKET INTRODUCTION
Enzyme replacement therapy is the process of replacement of enzymes with artificial enzymes in patients who are suffering from deficiency of enzymes. It involves intravenous (IV) infusions to correct the underlying enzyme deficiency.
MARKET DYNAMICS
Rising prevalence of rare disease is of the major factor driving the market growth. For instance, According to, Genetic and Rare Diseases Information Center the total number of Americans living with a rare disease is estimated at between 25-30 million. Moreover, growing demand for enzyme replacement therapy due to less side effects will further augment the market growth. However, alternate treatment options may impede the market growth.
MARKET SCOPE
`
The "Global Enzyme Replacement Therapy Market analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Enzyme Replacement Therapy Market with detailed market segmentation by enzyme type, therapeutic conditions, and geography. The Global Enzyme Replacement Therapy Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Enzyme Replacement Therapy Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Global Enzyme Replacement Therapy Market is segmented on the basis of enzyme type and therapeutic conditions. On the basis of enzyme type, market can be classified as pegademase, velaglucerase alfa, agalsidase beta, imiglucerase, taliglucerase, laronidase, alglucosidase alfa, galsulfase, idursulfase, pancreatic enzymes, and other enzymes. Based on therapeutic conditions, the market is divided into gaucher's disease, fabry's disease, pompe's disease, SCID, MPS, and others. ?
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Enzyme Replacement Therapy Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Enzyme Replacement Therapy Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Enzyme Replacement Therapy Market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Enzyme Replacement Therapy Market in these regions.
The report covers key developments in the Enzyme Replacement Therapy Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Enzyme Replacement Therapy Market are anticipated to lucrative growth opportunities in the future with the rising demand for Enzyme Replacement Therapy Market in the global market. Below mentioned is the list of few companies engaged in the Enzyme Replacement Therapy Market.
The report also includes the profiles of key Enzyme Replacement Therapy Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Shire Plc
- Sanofi S.A
- Biomarin Pharmaceutical Inc.
- AbbVie
- Alexion Pharmaceuticals Inc.
- Allergan plc.
- Horizon Pharma Public Limited Company
- Actelion (Janssen)
- Recordati Rare Diseases
- Protalix Biotherapeutics
- Amicus Therapeutics, Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Enzyme replacement therapy is the process of replacement of enzymes with artificial enzymes in patients who are suffering from deficiency of enzymes. It involves intravenous (IV) infusions to correct the underlying enzyme deficiency.
MARKET DYNAMICS
Rising prevalence of rare disease is of the major factor driving the market growth. For instance, According to, Genetic and Rare Diseases Information Center the total number of Americans living with a rare disease is estimated at between 25-30 million. Moreover, growing demand for enzyme replacement therapy due to less side effects will further augment the market growth. However, alternate treatment options may impede the market growth.
MARKET SCOPE
`
The "Global Enzyme Replacement Therapy Market analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Enzyme Replacement Therapy Market with detailed market segmentation by enzyme type, therapeutic conditions, and geography. The Global Enzyme Replacement Therapy Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Enzyme Replacement Therapy Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Global Enzyme Replacement Therapy Market is segmented on the basis of enzyme type and therapeutic conditions. On the basis of enzyme type, market can be classified as pegademase, velaglucerase alfa, agalsidase beta, imiglucerase, taliglucerase, laronidase, alglucosidase alfa, galsulfase, idursulfase, pancreatic enzymes, and other enzymes. Based on therapeutic conditions, the market is divided into gaucher's disease, fabry's disease, pompe's disease, SCID, MPS, and others. ?
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Enzyme Replacement Therapy Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Enzyme Replacement Therapy Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Enzyme Replacement Therapy Market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Enzyme Replacement Therapy Market in these regions.
The report covers key developments in the Enzyme Replacement Therapy Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Enzyme Replacement Therapy Market are anticipated to lucrative growth opportunities in the future with the rising demand for Enzyme Replacement Therapy Market in the global market. Below mentioned is the list of few companies engaged in the Enzyme Replacement Therapy Market.
The report also includes the profiles of key Enzyme Replacement Therapy Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Shire Plc
- Sanofi S.A
- Biomarin Pharmaceutical Inc.
- AbbVie
- Alexion Pharmaceuticals Inc.
- Allergan plc.
- Horizon Pharma Public Limited Company
- Actelion (Janssen)
- Recordati Rare Diseases
- Protalix Biotherapeutics
- Amicus Therapeutics, Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Enzyme Replacement Therapy - By Enzyme Type
1.3.2 Enzyme Replacement Therapy - By Therapeutic Conditions
1.3.3 Enzyme Replacement Therapy - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ENZYME REPLACEMENT THERAPY LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ENZYME REPLACEMENT THERAPY - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ENZYME REPLACEMENT THERAPY - GLOBAL MARKET ANALYSIS
6.1. ENZYME REPLACEMENT THERAPY - GLOBAL MARKET OVERVIEW
6.2. ENZYME REPLACEMENT THERAPY - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ENZYME REPLACEMENT THERAPY - REVENUE AND FORECASTS TO 2027 - ENZYME TYPE
7.1. OVERVIEW
7.2. ENZYME TYPE MARKET FORECASTS AND ANALYSIS
7.3. PEGADEMASE
7.3.1. Overview
7.3.2. Pegademase Market Forecast and Analysis
7.4. VELAGLUCERASE ALFA
7.4.1. Overview
7.4.2. Velaglucerase Alfa Market Forecast and Analysis
7.5. AGALSIDASE BETA
7.5.1. Overview
7.5.2. Agalsidase Beta Market Forecast and Analysis
7.6. IMIGLUCERASE
7.6.1. Overview
7.6.2. Imiglucerase Market Forecast and Analysis
7.7. TALIGLUCERASE
7.7.1. Overview
7.7.2. Taliglucerase Market Forecast and Analysis
7.8. LARONIDASE
7.8.1. Overview
7.8.2. Laronidase Market Forecast and Analysis
7.9. ALGLUCOSIDASE ALFA
7.9.1. Overview
7.9.2. Alglucosidase Alfa Market Forecast and Analysis
7.10. GALSULFASE
7.10.1. Overview
7.10.2. Galsulfase Market Forecast and Analysis
7.11. IDURSULFASE
7.11.1. Overview
7.11.2. Idursulfase Market Forecast and Analysis
7.12. PANCREATIC ENZYMES
7.12.1. Overview
7.12.2. Pancreatic Enzymes Market Forecast and Analysis
7.13. OTHER ENZYMES
7.13.1. Overview
7.13.2. Other Enzymes Market Forecast and Analysis
8. ENZYME REPLACEMENT THERAPY - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC CONDITIONS
8.1. OVERVIEW
8.2. THERAPEUTIC CONDITIONS MARKET FORECASTS AND ANALYSIS
8.3. GAUCHER'S DISEASE
8.3.1. Overview
8.3.2. Gaucher's Disease Market Forecast and Analysis
8.4. FABRY'S DISEASE
8.4.1. Overview
8.4.2. Fabry's Disease Market Forecast and Analysis
8.5. POMPE'S DISEASE
8.5.1. Overview
8.5.2. Pompe's Disease Market Forecast and Analysis
8.6. SCID
8.6.1. Overview
8.6.2. SCID Market Forecast and Analysis
8.7. MPS
8.7.1. Overview
8.7.2. MPS Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. ENZYME REPLACEMENT THERAPY REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Enzyme Replacement Therapy Overview
9.1.2 North America Enzyme Replacement Therapy Forecasts and Analysis
9.1.3 North America Enzyme Replacement Therapy Forecasts and Analysis - By Enzyme Type
9.1.4 North America Enzyme Replacement Therapy Forecasts and Analysis - By Therapeutic Conditions
9.1.5 North America Enzyme Replacement Therapy Forecasts and Analysis - By Countries
9.1.5.1 United States Enzyme Replacement Therapy
9.1.5.1.1 United States Enzyme Replacement Therapy by Enzyme Type
9.1.5.1.2 United States Enzyme Replacement Therapy by Therapeutic Conditions
9.1.5.2 Canada Enzyme Replacement Therapy
9.1.5.2.1 Canada Enzyme Replacement Therapy by Enzyme Type
9.1.5.2.2 Canada Enzyme Replacement Therapy by Therapeutic Conditions
9.1.5.3 Mexico Enzyme Replacement Therapy
9.1.5.3.1 Mexico Enzyme Replacement Therapy by Enzyme Type
9.1.5.3.2 Mexico Enzyme Replacement Therapy by Therapeutic Conditions
9.2. EUROPE
9.2.1 Europe Enzyme Replacement Therapy Overview
9.2.2 Europe Enzyme Replacement Therapy Forecasts and Analysis
9.2.3 Europe Enzyme Replacement Therapy Forecasts and Analysis - By Enzyme Type
9.2.4 Europe Enzyme Replacement Therapy Forecasts and Analysis - By Therapeutic Conditions
9.2.5 Europe Enzyme Replacement Therapy Forecasts and Analysis - By Countries
9.2.5.1 Germany Enzyme Replacement Therapy
9.2.5.1.1 Germany Enzyme Replacement Therapy by Enzyme Type
9.2.5.1.2 Germany Enzyme Replacement Therapy by Therapeutic Conditions
9.2.5.2 France Enzyme Replacement Therapy
9.2.5.2.1 France Enzyme Replacement Therapy by Enzyme Type
9.2.5.2.2 France Enzyme Replacement Therapy by Therapeutic Conditions
9.2.5.3 Italy Enzyme Replacement Therapy
9.2.5.3.1 Italy Enzyme Replacement Therapy by Enzyme Type
9.2.5.3.2 Italy Enzyme Replacement Therapy by Therapeutic Conditions
9.2.5.4 Spain Enzyme Replacement Therapy
9.2.5.4.1 Spain Enzyme Replacement Therapy by Enzyme Type
9.2.5.4.2 Spain Enzyme Replacement Therapy by Therapeutic Conditions
9.2.5.5 United Kingdom Enzyme Replacement Therapy
9.2.5.5.1 United Kingdom Enzyme Replacement Therapy by Enzyme Type
9.2.5.5.2 United Kingdom Enzyme Replacement Therapy by Therapeutic Conditions
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Enzyme Replacement Therapy Overview
9.3.2 Asia-Pacific Enzyme Replacement Therapy Forecasts and Analysis
9.3.3 Asia-Pacific Enzyme Replacement Therapy Forecasts and Analysis - By Enzyme Type
9.3.4 Asia-Pacific Enzyme Replacement Therapy Forecasts and Analysis - By Therapeutic Conditions
9.3.5 Asia-Pacific Enzyme Replacement Therapy Forecasts and Analysis - By Countries
9.3.5.1 Australia Enzyme Replacement Therapy
9.3.5.1.1 Australia Enzyme Replacement Therapy by Enzyme Type
9.3.5.1.2 Australia Enzyme Replacement Therapy by Therapeutic Conditions
9.3.5.2 China Enzyme Replacement Therapy
9.3.5.2.1 China Enzyme Replacement Therapy by Enzyme Type
9.3.5.2.2 China Enzyme Replacement Therapy by Therapeutic Conditions
9.3.5.3 India Enzyme Replacement Therapy
9.3.5.3.1 India Enzyme Replacement Therapy by Enzyme Type
9.3.5.3.2 India Enzyme Replacement Therapy by Therapeutic Conditions
9.3.5.4 Japan Enzyme Replacement Therapy
9.3.5.4.1 Japan Enzyme Replacement Therapy by Enzyme Type
9.3.5.4.2 Japan Enzyme Replacement Therapy by Therapeutic Conditions
9.3.5.5 South Korea Enzyme Replacement Therapy
9.3.5.5.1 South Korea Enzyme Replacement Therapy by Enzyme Type
9.3.5.5.2 South Korea Enzyme Replacement Therapy by Therapeutic Conditions
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Enzyme Replacement Therapy Overview
9.4.2 Middle East and Africa Enzyme Replacement Therapy Forecasts and Analysis
9.4.3 Middle East and Africa Enzyme Replacement Therapy Forecasts and Analysis - By Enzyme Type
9.4.4 Middle East and Africa Enzyme Replacement Therapy Forecasts and Analysis - By Therapeutic Conditions
9.4.5 Middle East and Africa Enzyme Replacement Therapy Forecasts and Analysis - By Countries
9.4.5.1 South Africa Enzyme Replacement Therapy
9.4.5.1.1 South Africa Enzyme Replacement Therapy by Enzyme Type
9.4.5.1.2 South Africa Enzyme Replacement Therapy by Therapeutic Conditions
9.4.5.2 Saudi Arabia Enzyme Replacement Therapy
9.4.5.2.1 Saudi Arabia Enzyme Replacement Therapy by Enzyme Type
9.4.5.2.2 Saudi Arabia Enzyme Replacement Therapy by Therapeutic Conditions
9.4.5.3 U.A.E Enzyme Replacement Therapy
9.4.5.3.1 U.A.E Enzyme Replacement Therapy by Enzyme Type
9.4.5.3.2 U.A.E Enzyme Replacement Therapy by Therapeutic Conditions
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Enzyme Replacement Therapy Overview
9.5.2 South and Central America Enzyme Replacement Therapy Forecasts and Analysis
9.5.3 South and Central America Enzyme Replacement Therapy Forecasts and Analysis - By Enzyme Type
9.5.4 South and Central America Enzyme Replacement Therapy Forecasts and Analysis - By Therapeutic Conditions
9.5.5 South and Central America Enzyme Replacement Therapy Forecasts and Analysis - By Countries
9.5.5.1 Brazil Enzyme Replacement Therapy
9.5.5.1.1 Brazil Enzyme Replacement Therapy by Enzyme Type
9.5.5.1.2 Brazil Enzyme Replacement Therapy by Therapeutic Conditions
9.5.5.2 Argentina Enzyme Replacement Therapy
9.5.5.2.1 Argentina Enzyme Replacement Therapy by Enzyme Type
9.5.5.2.2 Argentina Enzyme Replacement Therapy by Therapeutic Conditions
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ENZYME REPLACEMENT THERAPY, KEY COMPANY PROFILES
11.1. SHIRE PLC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. SANOFI S.A
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BIOMARIN PHARMACEUTICAL INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ABBVIE
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ALEXION PHARMACEUTICALS INC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ALLERGAN PLC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. HORIZON PHARMA PUBLIC LIMITED COMPANY
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. ACTELION (JANSSEN)
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. RECORDATI RARE DISEASES
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. PROTALIX BIOTHERAPEUTICS
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
11.11. AMICUS THERAPEUTICS, INC.
11.11.1. Key Facts
11.11.2. Business Description
11.11.3. Products and Services
11.11.4. Financial Overview
11.11.5. SWOT Analysis
11.11.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Enzyme Replacement Therapy - By Enzyme Type
1.3.2 Enzyme Replacement Therapy - By Therapeutic Conditions
1.3.3 Enzyme Replacement Therapy - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ENZYME REPLACEMENT THERAPY LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ENZYME REPLACEMENT THERAPY - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ENZYME REPLACEMENT THERAPY - GLOBAL MARKET ANALYSIS
6.1. ENZYME REPLACEMENT THERAPY - GLOBAL MARKET OVERVIEW
6.2. ENZYME REPLACEMENT THERAPY - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ENZYME REPLACEMENT THERAPY - REVENUE AND FORECASTS TO 2027 - ENZYME TYPE
7.1. OVERVIEW
7.2. ENZYME TYPE MARKET FORECASTS AND ANALYSIS
7.3. PEGADEMASE
7.3.1. Overview
7.3.2. Pegademase Market Forecast and Analysis
7.4. VELAGLUCERASE ALFA
7.4.1. Overview
7.4.2. Velaglucerase Alfa Market Forecast and Analysis
7.5. AGALSIDASE BETA
7.5.1. Overview
7.5.2. Agalsidase Beta Market Forecast and Analysis
7.6. IMIGLUCERASE
7.6.1. Overview
7.6.2. Imiglucerase Market Forecast and Analysis
7.7. TALIGLUCERASE
7.7.1. Overview
7.7.2. Taliglucerase Market Forecast and Analysis
7.8. LARONIDASE
7.8.1. Overview
7.8.2. Laronidase Market Forecast and Analysis
7.9. ALGLUCOSIDASE ALFA
7.9.1. Overview
7.9.2. Alglucosidase Alfa Market Forecast and Analysis
7.10. GALSULFASE
7.10.1. Overview
7.10.2. Galsulfase Market Forecast and Analysis
7.11. IDURSULFASE
7.11.1. Overview
7.11.2. Idursulfase Market Forecast and Analysis
7.12. PANCREATIC ENZYMES
7.12.1. Overview
7.12.2. Pancreatic Enzymes Market Forecast and Analysis
7.13. OTHER ENZYMES
7.13.1. Overview
7.13.2. Other Enzymes Market Forecast and Analysis
8. ENZYME REPLACEMENT THERAPY - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC CONDITIONS
8.1. OVERVIEW
8.2. THERAPEUTIC CONDITIONS MARKET FORECASTS AND ANALYSIS
8.3. GAUCHER'S DISEASE
8.3.1. Overview
8.3.2. Gaucher's Disease Market Forecast and Analysis
8.4. FABRY'S DISEASE
8.4.1. Overview
8.4.2. Fabry's Disease Market Forecast and Analysis
8.5. POMPE'S DISEASE
8.5.1. Overview
8.5.2. Pompe's Disease Market Forecast and Analysis
8.6. SCID
8.6.1. Overview
8.6.2. SCID Market Forecast and Analysis
8.7. MPS
8.7.1. Overview
8.7.2. MPS Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. ENZYME REPLACEMENT THERAPY REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Enzyme Replacement Therapy Overview
9.1.2 North America Enzyme Replacement Therapy Forecasts and Analysis
9.1.3 North America Enzyme Replacement Therapy Forecasts and Analysis - By Enzyme Type
9.1.4 North America Enzyme Replacement Therapy Forecasts and Analysis - By Therapeutic Conditions
9.1.5 North America Enzyme Replacement Therapy Forecasts and Analysis - By Countries
9.1.5.1 United States Enzyme Replacement Therapy
9.1.5.1.1 United States Enzyme Replacement Therapy by Enzyme Type
9.1.5.1.2 United States Enzyme Replacement Therapy by Therapeutic Conditions
9.1.5.2 Canada Enzyme Replacement Therapy
9.1.5.2.1 Canada Enzyme Replacement Therapy by Enzyme Type
9.1.5.2.2 Canada Enzyme Replacement Therapy by Therapeutic Conditions
9.1.5.3 Mexico Enzyme Replacement Therapy
9.1.5.3.1 Mexico Enzyme Replacement Therapy by Enzyme Type
9.1.5.3.2 Mexico Enzyme Replacement Therapy by Therapeutic Conditions
9.2. EUROPE
9.2.1 Europe Enzyme Replacement Therapy Overview
9.2.2 Europe Enzyme Replacement Therapy Forecasts and Analysis
9.2.3 Europe Enzyme Replacement Therapy Forecasts and Analysis - By Enzyme Type
9.2.4 Europe Enzyme Replacement Therapy Forecasts and Analysis - By Therapeutic Conditions
9.2.5 Europe Enzyme Replacement Therapy Forecasts and Analysis - By Countries
9.2.5.1 Germany Enzyme Replacement Therapy
9.2.5.1.1 Germany Enzyme Replacement Therapy by Enzyme Type
9.2.5.1.2 Germany Enzyme Replacement Therapy by Therapeutic Conditions
9.2.5.2 France Enzyme Replacement Therapy
9.2.5.2.1 France Enzyme Replacement Therapy by Enzyme Type
9.2.5.2.2 France Enzyme Replacement Therapy by Therapeutic Conditions
9.2.5.3 Italy Enzyme Replacement Therapy
9.2.5.3.1 Italy Enzyme Replacement Therapy by Enzyme Type
9.2.5.3.2 Italy Enzyme Replacement Therapy by Therapeutic Conditions
9.2.5.4 Spain Enzyme Replacement Therapy
9.2.5.4.1 Spain Enzyme Replacement Therapy by Enzyme Type
9.2.5.4.2 Spain Enzyme Replacement Therapy by Therapeutic Conditions
9.2.5.5 United Kingdom Enzyme Replacement Therapy
9.2.5.5.1 United Kingdom Enzyme Replacement Therapy by Enzyme Type
9.2.5.5.2 United Kingdom Enzyme Replacement Therapy by Therapeutic Conditions
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Enzyme Replacement Therapy Overview
9.3.2 Asia-Pacific Enzyme Replacement Therapy Forecasts and Analysis
9.3.3 Asia-Pacific Enzyme Replacement Therapy Forecasts and Analysis - By Enzyme Type
9.3.4 Asia-Pacific Enzyme Replacement Therapy Forecasts and Analysis - By Therapeutic Conditions
9.3.5 Asia-Pacific Enzyme Replacement Therapy Forecasts and Analysis - By Countries
9.3.5.1 Australia Enzyme Replacement Therapy
9.3.5.1.1 Australia Enzyme Replacement Therapy by Enzyme Type
9.3.5.1.2 Australia Enzyme Replacement Therapy by Therapeutic Conditions
9.3.5.2 China Enzyme Replacement Therapy
9.3.5.2.1 China Enzyme Replacement Therapy by Enzyme Type
9.3.5.2.2 China Enzyme Replacement Therapy by Therapeutic Conditions
9.3.5.3 India Enzyme Replacement Therapy
9.3.5.3.1 India Enzyme Replacement Therapy by Enzyme Type
9.3.5.3.2 India Enzyme Replacement Therapy by Therapeutic Conditions
9.3.5.4 Japan Enzyme Replacement Therapy
9.3.5.4.1 Japan Enzyme Replacement Therapy by Enzyme Type
9.3.5.4.2 Japan Enzyme Replacement Therapy by Therapeutic Conditions
9.3.5.5 South Korea Enzyme Replacement Therapy
9.3.5.5.1 South Korea Enzyme Replacement Therapy by Enzyme Type
9.3.5.5.2 South Korea Enzyme Replacement Therapy by Therapeutic Conditions
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Enzyme Replacement Therapy Overview
9.4.2 Middle East and Africa Enzyme Replacement Therapy Forecasts and Analysis
9.4.3 Middle East and Africa Enzyme Replacement Therapy Forecasts and Analysis - By Enzyme Type
9.4.4 Middle East and Africa Enzyme Replacement Therapy Forecasts and Analysis - By Therapeutic Conditions
9.4.5 Middle East and Africa Enzyme Replacement Therapy Forecasts and Analysis - By Countries
9.4.5.1 South Africa Enzyme Replacement Therapy
9.4.5.1.1 South Africa Enzyme Replacement Therapy by Enzyme Type
9.4.5.1.2 South Africa Enzyme Replacement Therapy by Therapeutic Conditions
9.4.5.2 Saudi Arabia Enzyme Replacement Therapy
9.4.5.2.1 Saudi Arabia Enzyme Replacement Therapy by Enzyme Type
9.4.5.2.2 Saudi Arabia Enzyme Replacement Therapy by Therapeutic Conditions
9.4.5.3 U.A.E Enzyme Replacement Therapy
9.4.5.3.1 U.A.E Enzyme Replacement Therapy by Enzyme Type
9.4.5.3.2 U.A.E Enzyme Replacement Therapy by Therapeutic Conditions
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Enzyme Replacement Therapy Overview
9.5.2 South and Central America Enzyme Replacement Therapy Forecasts and Analysis
9.5.3 South and Central America Enzyme Replacement Therapy Forecasts and Analysis - By Enzyme Type
9.5.4 South and Central America Enzyme Replacement Therapy Forecasts and Analysis - By Therapeutic Conditions
9.5.5 South and Central America Enzyme Replacement Therapy Forecasts and Analysis - By Countries
9.5.5.1 Brazil Enzyme Replacement Therapy
9.5.5.1.1 Brazil Enzyme Replacement Therapy by Enzyme Type
9.5.5.1.2 Brazil Enzyme Replacement Therapy by Therapeutic Conditions
9.5.5.2 Argentina Enzyme Replacement Therapy
9.5.5.2.1 Argentina Enzyme Replacement Therapy by Enzyme Type
9.5.5.2.2 Argentina Enzyme Replacement Therapy by Therapeutic Conditions
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ENZYME REPLACEMENT THERAPY, KEY COMPANY PROFILES
11.1. SHIRE PLC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. SANOFI S.A
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BIOMARIN PHARMACEUTICAL INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ABBVIE
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ALEXION PHARMACEUTICALS INC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ALLERGAN PLC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. HORIZON PHARMA PUBLIC LIMITED COMPANY
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. ACTELION (JANSSEN)
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. RECORDATI RARE DISEASES
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. PROTALIX BIOTHERAPEUTICS
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
11.11. AMICUS THERAPEUTICS, INC.
11.11.1. Key Facts
11.11.2. Business Description
11.11.3. Products and Services
11.11.4. Financial Overview
11.11.5. SWOT Analysis
11.11.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies
1. Shire Plc
2. Sanofi S.A
3. Biomarin Pharmaceutical Inc.
4. AbbVie
5. Alexion Pharmaceuticals Inc.
6. Allergan plc.
7. Horizon Pharma Public Limited Company
8. Actelion (Janssen)
9. Recordati Rare Diseases
10. Protalix Biotherapeutics
11. Amicus Therapeutics, Inc.
1. Shire Plc
2. Sanofi S.A
3. Biomarin Pharmaceutical Inc.
4. AbbVie
5. Alexion Pharmaceuticals Inc.
6. Allergan plc.
7. Horizon Pharma Public Limited Company
8. Actelion (Janssen)
9. Recordati Rare Diseases
10. Protalix Biotherapeutics
11. Amicus Therapeutics, Inc.